23.06.2026 Chris Neff neuer Geschäftsführer von Merck Österreichmore about Chris Neff neuer Geschäftsführer von Merck Österreich
23.06.2026 MedUni Vienna: Initial basis established for a standardised definition of arterial functional mitral regurgitation in heart diseasemore about MedUni Vienna: Initial basis established for a standardised definition of arterial functional mitral regurgitation in heart disease
23.06.2026 MedUni Vienna: Three ERC Advanced Grants linked to the Medical University of Viennamore about MedUni Vienna: Three ERC Advanced Grants linked to the Medical University of Vienna
23.06.2026 BMFWF: 31,6 Mio. Euro für den Forschungsstandort: Österreich behauptet sich in der europäischen Spitzenforschungmore about BMFWF: 31,6 Mio. Euro für den Forschungsstandort: Österreich behauptet sich in der europäischen Spitzenforschung
22.06.2026 Graph Therapeutics Brings Total Funding to Over $10 Million to Advance Therapeutics Programs in Inflammation and Immunologymore about Graph Therapeutics Brings Total Funding to Over $10 Million to Advance Therapeutics Programs in Inflammation and Immunology
22.06.2026 xbio Biotech Enterprise Masterclass concludes fourth editionmore about xbio Biotech Enterprise Masterclass concludes fourth edition
22.06.2026 MedUniVienna: Testing cancer treatments in the body’s own tumour microenvironmentmore about MedUniVienna: Testing cancer treatments in the body’s own tumour microenvironment
22.06.2026 Fraunhofer Austria: Kürzere OP-Zeiten bei Leberkrebs dank neuer Analyse-Methodemore about Fraunhofer Austria: Kürzere OP-Zeiten bei Leberkrebs dank neuer Analyse-Methode
19.06.2026 MedUni Vienna: Neural stimulation and exoskeletons improve hand function following neurological injuriesmore about MedUni Vienna: Neural stimulation and exoskeletons improve hand function following neurological injuries
18.06. - 18.06.2026 Hattmannsdorfer/Gerzabek: CDG-Preis 2026 für Paradigmenwechsel in den Life-Sciencesmore about Hattmannsdorfer/Gerzabek: CDG-Preis 2026 für Paradigmenwechsel in den Life-Sciences
18.06.2026 F2G and Shionogi announce positive topline results from global Phase 3 OASIS study evaluating oral olorofim versus AmBisome® followed by Standard of Care in patients with invasive aspergillosismore about F2G and Shionogi announce positive topline results from global Phase 3 OASIS study evaluating oral olorofim versus AmBisome® followed by Standard of Care in patients with invasive aspergillosis
18.06.2026 Wundheilung: LBG- und BOKU-Forschung zeigt schnelle Zellalterung als zentralen Teil der Heilungmore about Wundheilung: LBG- und BOKU-Forschung zeigt schnelle Zellalterung als zentralen Teil der Heilung